UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$593.14

Market cap

$25.26B

P/E Ratio

20.76

Dividend/share

N/A

EPS

$28.57

Enterprise value

$24.07B

?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 39
Relative Profitability: Rel. Profitability: 93

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to ...

Highlights
The stock's P/E is 44% above its 5-year quarterly average of 14.5 and 14% above its last 4 quarters average of 18.3
The quick ratio has declined by 31% year-on-year and by 21% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.42%
1 week
4.85%
1 month
7.82%
1 year
28.51%
YTD
21.73%
QTD
9.46%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$3.19B
Gross profit
$2.75B
Operating income
$1.32B
Net income
$1.23B
Gross margin
86.3%
Net margin
38.6%
The company's operating margin fell by 13% YoY and by 7% QoQ
The operating income has contracted by 12% YoY and by 6% from the previous quarter
The net margin has contracted by 7% from the previous quarter and by 5% YoY
UNITED THERAPEUTICS's net income has decreased by 6% QoQ and by 3.2% YoY

Price vs fundamentals

How does UTHR's price correlate with its fundamentals

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
20.76
P/B
4.05
P/S
7.95
EV/EBIT
15.84
EV/EBITDA
14.9
EV/Sales
7.55
The stock's P/E is 44% above its 5-year quarterly average of 14.5 and 14% above its last 4 quarters average of 18.3
The company's EPS fell by 6% QoQ
UTHR's price to book (P/B) is 63% higher than its 5-year quarterly average of 2.5 and 10% higher than its last 4 quarters average of 3.7
The equity has declined by 4.8% year-on-year
The stock's P/S is 43% above its 5-year quarterly average of 5.6 and 8% above its last 4 quarters average of 7.4

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The company's return on sales fell by 12% YoY and by 5% QoQ
UNITED THERAPEUTICS's return on assets has decreased by 5% QoQ
The ROE has contracted by 5% from the previous quarter but it has grown by 2.1% YoY
The ROIC has contracted by 5% YoY and by 3.2% from the previous quarter

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has declined by 31% year-on-year and by 21% since the previous quarter
The current ratio has contracted by 28% YoY and by 20% from the previous quarter
The debt is 100% less than the equity
The equity has declined by 4.8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.